October 31, 2019
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next… Read More
learn more
October 16, 2019
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR)… Read More
learn more
October 1, 2019
Novocure to Report Third Quarter 2019 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine… Read More
learn more